A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma.
Yu W, Li P, Zhou L, Yang M, Ye S, Zhu D, Huang J, Yao X, Zhang Y, Li L, Zhao J, Zhu K, Li J, Zheng C, Lan L, Wan H, Yao Y, Zhang H, Zhou D, Jin J, Liang A.
Yu W, et al. Among authors: zhu d.
Blood. 2025 Jan 15:blood.2024026401. doi: 10.1182/blood.2024026401. Online ahead of print.
Blood. 2025.
PMID: 39813680